Prostate cancer screenings using blood tests have sparked debate over their effectiveness and potential risks, especially among older men. The US Preventive Services Task Force has provided conflicting guidance on the use of these tests, which measure prostate-specific antigen (PSA) levels in the blood.
Doctors and public health experts acknowledge that PSA testing alone is not an ideal cancer screening method. It can lead to false positives, overtreatment, and painful biopsies. However, some oncologists argue that PSA testing is beneficial when used judiciously, particularly for identifying aggressive cancers.
The key is to target treatment for high-risk patients while monitoring low-risk cases. The US Preventive Services Task Force recommends discussing screening with healthcare providers for men aged 55-69 and against screening for those over 70. However, experts agree that the current guidance may not be sufficient.
New approaches to prostate cancer screening have emerged, focusing on targeted biopsies, MRI scans, and active surveillance for low-risk cases. These methods aim to improve accuracy and reduce unnecessary treatments while still detecting life-threatening cancers.
Ultimately, the decision to undergo PSA testing should be made after a thorough discussion with healthcare providers. While some men may welcome shared decision-making, others find it daunting. For now, primary care physicians recommend that men discuss their preferences with their doctors before making a decision.
As the debate continues, medical experts hope for new guidelines that address the complexities of prostate cancer screening. The goal is to strike a balance between saving lives and minimizing unnecessary treatments.
Source: https://www.npr.org/sections/shots-health-news/2025/05/21/nx-s1-5405613/prostate-cancer-psa-test-age